2024.07.17
On July 5, 2024, IASO Biotechnology and Innovent Biologics announced the execution of a series of cooperation agreements with respect to IASO Biotechnology's acquisition of the income rights and intellectual property license of the cooperative product, FUCASO®, from Innovent Biologics, as well as Innovent Biologics' equity investment in IASO Biotechnology.
According to the terms of the agreements, IASO Biotechnology will purchase the relevant interests held by Innovent Biologics under the original BCMA CAR-T cooperation agreement at the agreed price. Innovent Biologics will make an equity investment in IASO Biotechnology at the same price, thereby holding 18% of the latter's shares. Under this new strategic cooperation framework, both parties will achieve a high level of resource integration in cell immunotherapy. IASO Biotechnology will obtain the global commercialization rights and intellectual property license for FUCASO® (Equecabtagene Autoleucel) and assume the sole responsibility for the development, production, and sales of the product; Innovent Biologics will become a strategic shareholder of IASO Biotechnology.
JunHe was entrusted by IASO Biotechnology to review and modify the transaction documents in relation to the intellectual property license. Throughout the transaction process, JunHe provided professional, efficient and meticulous legal services, earning high praise from the client.
Partner HAO, Hao (Gerry) led JunHe’s team in this project and partner DONG, Ming provided significant assistance in the bankruptcy law-related matters.
